In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Some Big Year-End Dealmaking From SkyePharma

Executive Summary

SkyePharma keeps its promise of profitability in 2002 by licensing its two most prominent pipeline candidates to Endo Pharmaceuticals. But now that the company has reached that benchmark, longer-term growth may require it to develop its own commercial capabilities.

You may also be interested in...

Medeus Deals Quickly for Skye's Depomorphine

Newly-created Medeus Pharma hasn't waited long to sign its first in-licensing deal. Only two months after its creation, through the acquisition of Elan's European sales and marketing infrastructure, the firm has secured European rights to SkyePharma's sustained-release post-op pain treatment DepoMorphine for €100 million. SkyePharma continues shifting the source of its revenues from milestone payments to more predictable royalties; Medeus flexes its muscle as a viable, fast-moving competitor to larger pan-European in-licensers.

Delivering Profits at SkyePharma

SkyePharma fulfilled its profitability promise in 2002. Yet warnings of a revenue slip in the middle of 2003 have highlighted the group's reliance on the timing of uncertain milestones. But by building up its clinical and regulatory capabilities, increasing the proportion of its revenues derived from royalties, and leveraging a full pipeline which includes improved biologics, SkyePharma aims to increase its development control over its own and partners' programs and thereby maintain and grow its newfound profitability.

Skyepharma:Trying To Take Off From a Short Runway

Since 1998, through a series of inexpensive acquisitions, SkyePharma has assembled a wide range of drug delivery technologies, positioning itself as a one stop shop. But the company still has to convince both its customers, and its investors, that it has not sacrificed quality for quantity.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts